Taipei-based precision oncology firm Anbogen Therapeutics Inc. drew $12.5 million in a series A funding round to propel two major clinical assets in its cancer pipeline.
The week closed out with two IPOs on their way in. Alto Neuroscience Inc. (NASDAQ:ANRO) and Fractyl Health Inc. (NASDAQ:GUTS) both debuted on Wall Street with offerings looking to raise combined $238.6 million.
A rare pediatric disease designation for its achondroplasia treatment and a subsequent $200 million private placement boosted shares of Tyra Biosciences Inc. on Feb. 2 by 29.3%.
Cognito Therapeutics Inc. closed a $35 million extension to the series B fundraising round it started in 2023, bringing the total for the round to $108 million and the total funding to date to $128 million. Cognito is developing Spectris, a wearable medical device that provides visual and auditory stimulation for the treatment of Alzheimer’s disease and other neurological disorders.
Halia Therapeutics Inc. has, its CEO confidently asserts, taken an atypical road to building its infrastructure and financing. The Lehi, Utah-based company just completed a $30 million series C financing to further develop its lead asset, a selective and orally bioavailable first-in-class NLRP3/NEK7 inflammasome inhibitor.
RSS
